ESC 365 - RAASi therapy benefit and challenges in cardio-renal patients.

HFA Premium Access

RAASi therapy benefit and challenges in cardio-renal patients.

Session: Enabling and optimizing Renin-Angiotensin-Aldosterone-System inhibitors (RAASi) therapy in cardio-renal patients by controlling potassium levels

Topic: Miscellaneous

Speaker: Professor L. Lund (Stockholm, SE)

Sponsored by Vifor Pharma / Vifor Fresenius Medical Care Renal Pharma

Event: Heart Failure 2017 - 4th World Congress on Acute Heart Failure

Congress Presentation

Add to my library

About the speaker

Professor Lars Lund

Karolinska University Hospital, Stockholm (Sweden)

61 presentations

10 followers

5 more presentations in this session

Welcome and introduction.

Treatment strategies to manage hyperkalemia and control potassium levels.

Speaker: Professor S. Anker (Berlin, DE)

Changing the treatment paradigm of hyperkalemia management to enable and optimize RAASi therapy.

Speaker: Professor J. Butler (Dallas, US)

Panel discussion.

Speaker: Professor B. Pitt (Ann Arbor, US)

Summary and conclusions.

Speaker: Professor F. Zannad (Vandoeuvre-Les-Nancy, FR)

Access the full session

Enabling and optimizing Renin-Angiotensin-Aldosterone-System inhibitors (RAASi) therapy in cardio-renal patients by controlling potassium levels

Speakers: Professor L. Lund, Professor S. Anker, Professor J. Butler, Professor B. Pitt, Professor F. Zannad

About the event

Heart Failure 2017 - 4th World Congress on Acute Heart Failure

29 April - 2 May 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources